AN OPEN LABEL, MULTI-CENTER PASIREOTIDE ROLL-OVER PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PREVIOUS NOVARTIS-SPONSORED PASIREOTIDE STUDY AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED PASIREOTIDE TREATMENT
- Registry ID
- CSOM230B2412
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Study type
- INTERVENTIONAL
- Sponsor
- RECORDATI RARE DISEASES CANADA INC
- Start date
- 2013-09-23
- Completion date
- 2023-07-24
- Last update
- 2013-04-10
Conditions
- PITUIARY TUMOR
- PROSTATE CANCER
- MELANOMA
- ACROMEGALY
- DUMPING SYNDROME
- CUSHING'S DISEASE
- MELANOMA NEGATIVE FOR BRAF
- ECTOPIC ACTH SECRETING (EAS) TUMORS
- MELANOMA NEGATIVE FOR NRAS
Related clinical trials
- A PHASE I/II OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF AZD6621, A T -CELL-ENGAGING ANTIBODY THAT TARGETS STEAP2, CD3, AND CD8 IN ADULT PARTICIPANTS WITH METASTATIC PROSTATE CANCER (ACTIVATED-4-PC)
- Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial
- Electrochemotherapy-Induced Changes in Tumor Microenvironment in Cutaneous Melanoma
- A PHASE 1/2 FIRST-TIME-IN-HUMAN, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE OPTIMIZATION STUDY OF GSK5471713 IN ADULT PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
- A PHASE II, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF THE COMBINATION OF INAVOLISIB PLUS ENZALUTAMIDE VERSUS PHYSICIAN'S CHOICE OF ARPI OR DOCETAXEL IN PATIENTS WITH METASTATIC CASTRATIONRESISTANT PROSTATE CANCER
- A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF NEOADJUVANT DAROVASERTIB IN
SUBJECTS WITH PRIMARY NON-METASTATIC UVEAL MELANOMA (OPTIMUM-10)
View on source registry